Contributions of neurologists to diagnostic timelines of ALS and thinkALS as an early referral instrument for clinicians.

To evaluate neurologists and other clinicians' contributions to U.S. ALS diagnostic timelines.

Personal Testimony About Dealing with Loss and Self-Care.

As an interfaith hospital chaplain and a Christian, navigating the profound emotional terrain of grief and loss is both a professional duty and a deeply personal journey. Attending the funerals of two close friends has brought out the interplay between my role as a spiritual caregiver and my own vulnerability. In reflection, I realize the importance of self-care and the reminder that in offering comfort and empathy, I must first find it within myself.

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.

With multiple PD-(L)1 inhibitors approved across dozens of indications by the US Food and Drug Administration, the number of patients exposed to these agents in adjuvant, first-line metastatic, second-line metastatic, and refractory treatment settings is increasing rapidly. Although some patients will experience durable benefit, many have either no clinical response or see their disease progress following an initial response to therapy. There is a significant need to identify therapeutic approaches to overcome resistance and confer clinical benefits for these patients.

Adopting recommendations for implementing patient involvement in cancer research: a funder's approach.

Background: The role of patients in cancer research is undergoing a significant evolution as all stakeholders seek to enhance the level of direct patient involvement in the design and development of clinical trials. However, there are significant hurdles that patients, patient advocates, laboratory researchers, clinical investigators, and funding institutions must overcome to implement relevant patient involvement in all aspects of biomedical research. By using innovative grant funding models, philanthropic organizations can lead the field in overcoming these challenges.

Leveraging Patient Preference Information in Medical Device Clinical Trial Design.

Use of robust, quantitative tools to measure patient perspectives within product development and regulatory review processes offers the opportunity for medical device researchers, regulators, and other stakeholders to evaluate what matters most to patients and support the development of products that can best meet patient needs. The medical device innovation consortium (MDIC) undertook a series of projects, including multiple case studies and expert consultations, to identify approaches for utilizing patient preference information (PPI) to inform clinical trial design in the US regulatory context. Based on these activities, this paper offers a cogent review of considerations and opportunities for researchers seeking to leverage PPI within their clinical trial development programs and highlights future directions to enhance this field.